Morgan Stanley reiterates Tesla stock rating on capex expansion By Investing.com

The market is starting to re-rate Tesla less as a software/autonomy multiple and more as a capital cycle story. When a company with already-stretched valuation is forced to fund a multi-year industrial buildout, the near-term equity thesis becomes dominated by dilution risk to free cash flow rather than by headline growth rates; that typically compresses multiples before the eventual operating leverage shows up. The second-order effect is that every incremental dollar of capex must be justified by evidence of faster monetization in autonomy, energy storage, or compute, otherwise the stock trades like a high-beta manufacturing name with optionality rather than a category-defining platform.

The near-term winners are likely to be suppliers and infrastructure enablers, not TSLA equity holders. Higher spending on semis, compute, factory tooling, and energy manufacturing should support a broader supplier basket with more visible cash returns, while competing EV OEMs may benefit from Tesla's slower rollout cadence if they can exploit the window on product refreshes and incentives. The risk is that validation-driven launches create a longer gap between narrative and revenue, which matters because a 6-12 month delay can mean multiple turns of valuation compression if earnings revisions keep drifting lower.

The main contrarian point is that the market may already be discounting too much perfection on autonomy timelines but not enough on capital intensity. If Tesla proves that higher capex is converting into durable unit economics or a credible robotaxi/humanoid milestone, the stock can re-rate sharply; if not, the downside asymmetry is meaningful because the balance between margin pressure and spending growth tends to punish long-duration equity. The catalyst path to watch is not next quarter's delivery print, but whether management can show declining capex intensity by the second half of 2026 without sacrificing roadmap credibility.